Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
NEW YORK, Feb. 27, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Infectious Diseases Therapeutics Market-Influenza, RSV, Chlamydia, and Gonorrhoea
Persistent Unmet Need for Treatment Fuels Novel Antiviral/Antibacterial Drug Development
• Ribavirin, the only approved antiviral directed at the human respiratory syncytial virus (RSV), is modestly effective. Variable response, development of resistance and viral breakthrough, along with poor tolerability and suboptimal dosing regimens, however, do not support the regular use of ribavirin.
• Successful commercialisation of next-generation antibodies and the launch of cheaper biosimilar versions of Synagis are likely to result in improved immunoprophylactic therapy for RSV.
• Clinical trials investigating the development of vaccines for the prevention of RSV are ongoing. Market participants strive to overcome challenges associated with incomplete immune response in very naive infants, and strain variability.
Influenza Antivirals and Vaccines
• Antivirals, particularly second and third-generation neuraminidase inhibitors, are quite effective in the treatment of influenza. However, the development of resistance to antivirals remains a key challenge.
• Egg-based vaccines, for the prevention of both seasonal and pandemic influenza, are currently in use.
• The imminent arrival of novel innovative vaccine technologies, in terms of adjuvants, carriers, and drug delivery mechanisms, has resulted in significant sophistication levels in egg-based vaccines for the prevention of seasonal and pandemic influenza.
• Nevertheless, several newer classes of antivirals, cell-based vaccines, and non-invasive drug delivery systems are currently being investigated to improve efficacy and patient compliance.
• The currently available antibacterials directed against uncomplicated urogenital chlamydia are quite effective and offer a therapeutic cure rate of over xx%.
• As the chlamydia trachomatis infection is predominantly asymptomatic, diagnosis of the disease still remains a key challenge. Hence, the majority of the clinical development activity is directed towards the assessment and testing of the disease.
• Clinical pipelines are very dry with few new compounds being investigated for the treatment of chlamydia. Minimal research and development (R&D) activity is carried out in this market segment.
• The currently available antibacterials directed against Neisseria gonorrhoea are moderately effective. The development of resistance to almost every recommended antibiotic for the treatment of gonorrhoea makes treatment complicated.
• Increased assessment of combination therapies and the investigation of newer classes of antibiotics are likely to contribute to significant cure rates of over xx%.
• Cephalosporins, such as ceftriaxone and cefixime, are currently looked upon as the last line of defence for gonorrhoea, despite a few recently reported cases of resistance to these antibiotics.
• Currently, Cempra Inc. is evaluating solithromycin in phase I/II trials for the treatment of bacterial pneumonia, uncomplicated urogenital gonorrhoea, and other sexually transmitted infections (STIs)
Methodology and Scope
• This research service focuses on antibiotic/antibacterial therapeutics for the treatment of infection by blood-borne (sexually transmitted) bacteria, which include chlamydia trachomatis and Neisseria gonorrhoea as well as antiviral therapeutics for infection by vector borne pathogens such as the influenza virus and the human respiratory syncytial virus (RSV).
• A product and pipeline assessment is provided for marketed and investigational products and combination regimens for the treatment of chlamydia trachomatis, Neisseria gonorrhoea, influenza and RSV infections. Segmentation by drug class is provided along with additional supporting information, such as clinical trial timelines, results and epidemiology.
• The information contained in this research service was derived from published sources, including the following: Disease organisation web sites; public health organisation web sites; company publications including annual reports, US Securities and Exchange Commission (SEC) filings, and press releases; government public sources; and published articles in scientific journals.
Evolution of Standard of Care
Methodology and Scope
RSV Therapeutics Market
RSV-Competitive Landscape: Marketed Products and Products in Development
RSV-Key Marketed Product Synopsis
RSV Product Dashboard
RSV-Major Ongoing/Recently Completed Clinical Trials
RSV-Major Ongoing/Recently Completed Clinical Trials Detailed Findings
RSV-Timeline of Key Events
RSV-Key Company to Watch
RSV-Key Companies with Best Practices
RSV-New Market Opportunities
RSV-Merger, Acquisition, and Partnership Assessment
Influenza Therapeutics Market
Influenza Antivirals Segment
Influenza Antivirals-Key Marketed Product Synopsis
Influenza Antivirals-Product Dashboard
Influenza Antivirals-Pipeline Synopsis
Influenza Antivirals-Major Ongoing/Recently Completed Clinical Trials
Influenza Antivirals-Major Ongoing/Recently Completed Clinical Trials Detailed Findings
Influenza Antivirals-Timeline of Key Events
Influenza Vaccines Segment
Influenza Vaccines-Key Marketed Product Synopsis
Influenza Vaccines-Pipeline Synopsis
Influenza Vaccines-Key Companies to Watch
Influenza Vaccines-Merger, Acquisition and Partnership Assessment
Chlamydia Therapeutics Market
Chlamydia-Key Marketed Product Synopsis
Chlamydia-Major Ongoing/Recently Completed Clinical Trials
Chlamydia-Major Ongoing/Recently Completed Clinical Trials Detailed Findings
Chlamydia-Timeline of Key Events
Chlamydia-Key Company to Watch
Gonorrhoea Therapeutics Market
Gonorrhoea-Key Marketed Product Synopsis
Gonorrhoea-Major Ongoing/Recently Completed Clinical Trials
Gonorrhoea-Major Ongoing/Recently Completed Clinical Trials Detailed Findings
Gonorrhoea-Timeline of Key Events
Gonorrhoea-Key Company to Watch
The Frost & Sullivan Story
To order this report: Global Infectious Diseases Therapeutics Market-Influenza, RSV, Chlamydia, and Gonorrhoea
Contact Clare: firstname.lastname@example.org
Intl: +1 339-368-6001
©2012 PR Newswire. All Rights Reserved.